PTC Therapeutics, Inc PTC Therapeutics (NASDAQ: PTCT) Confirm FDA Approves Label Extension for Evrysdi PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed that US FDA has authorized a label extension for Evrysdi (risdiplam) to include infants under 2 months old with spinal muscular atrophy (SMA). Evrysdi